Business Description
Enzon Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US2939041081
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.07 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.6 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 78.07 | |||||
9-Day RSI | 76.2 | |||||
14-Day RSI | 70.81 | |||||
6-1 Month Momentum % | -41.71 | |||||
12-1 Month Momentum % | -57.97 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 89.19 | |||||
Quick Ratio | 89.19 | |||||
Cash Ratio | 88.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | 49.5 | |||||
ROA % | 3.19 | |||||
ROIC % | -464.05 | |||||
ROCE % | -2.35 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | N/A | |||||
PE Ratio without NRI | N/A | |||||
Shiller PE Ratio | 1.02 | |||||
PB Ratio | 3.3 | |||||
Price-to-Tangible-Book | 4.13 | |||||
Price-to-Free-Cash-Flow | 8.06 | |||||
Price-to-Operating-Cash-Flow | 8.06 | |||||
EV-to-EBIT | 32.47 | |||||
EV-to-EBITDA | 32.47 | |||||
EV-to-FCF | -25.42 | |||||
Price-to-Projected-FCF | 0.92 | |||||
Price-to-Net-Current-Asset-Value | 4.13 | |||||
Price-to-Net-Cash | 4.13 | |||||
Earnings Yield (Greenblatt) % | 3.08 | |||||
FCF Yield % | 12.88 | |||||
Forward Rate of Return (Yacktman) % | 198.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Enzon Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | 0 | ||
Beta | -0.3 | ||
Volatility % | 72.58 | ||
14-Day RSI | 70.81 | ||
14-Day ATR (€) | 0.004798 | ||
20-Day SMA (€) | 0.06735 | ||
12-1 Month Momentum % | -57.97 | ||
52-Week Range (€) | 0.0465 - 0.195 | ||
Shares Outstanding (Mil) | 74.21 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Enzon Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Enzon Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Enzon Pharmaceuticals Inc Frequently Asked Questions
What is Enzon Pharmaceuticals Inc(STU:EZ1)'s stock price today?
When is next earnings date of Enzon Pharmaceuticals Inc(STU:EZ1)?
Does Enzon Pharmaceuticals Inc(STU:EZ1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |